These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9679557)

  • 1. Glutathione based approaches to improving cancer treatment.
    Kauvar LM; Morgan AS; Sanderson PE; Henner WD
    Chem Biol Interact; 1998 Apr; 111-112():225-38. PubMed ID: 9679557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.
    Morgan AS; Sanderson PE; Borch RF; Tew KD; Niitsu Y; Takayama T; Von Hoff DD; Izbicka E; Mangold G; Paul C; Broberg U; Mannervik B; Henner WD; Kauvar LM
    Cancer Res; 1998 Jun; 58(12):2568-75. PubMed ID: 9635580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular response to a glutathione S-transferase P1-1 activated prodrug.
    Rosario LA; O'Brien ML; Henderson CJ; Wolf CR; Tew KD
    Mol Pharmacol; 2000 Jul; 58(1):167-74. PubMed ID: 10860939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione analogues in cancer treatment.
    Hamilton D; Batist G
    Curr Oncol Rep; 2004 Mar; 6(2):116-22. PubMed ID: 14751089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets.
    Townsend DM; Findlay VL; Tew KD
    Methods Enzymol; 2005; 401():287-307. PubMed ID: 16399394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLK-286.
    Verschraegen CF; Smith HO; Lee FC; Cathcart C; Norenberg JP
    IDrugs; 2004 Aug; 7(8):771-81. PubMed ID: 15334311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo.
    Li S; Li C; Jin S; Liu J; Xue X; Eltahan AS; Sun J; Tan J; Dong J; Liang XJ
    Biomaterials; 2017 Nov; 144():119-129. PubMed ID: 28834763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of TER286 against human tumor colony-forming units.
    Izbicka E; Lawrence R; Cerna C; Von Hoff DD; Sanderson PE
    Anticancer Drugs; 1997 Apr; 8(4):345-8. PubMed ID: 9180387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphono analogs of glutathione: inhibition of glutathione transferases, metabolic stability, and uptake by cancer cells.
    Kunze T; Heps S
    Biochem Pharmacol; 2000 Apr; 59(8):973-81. PubMed ID: 10692562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death.
    Singh S
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):1-15. PubMed ID: 25143300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eribulin: a novel cytotoxic chemotherapy agent.
    Preston JN; Trivedi MV
    Ann Pharmacother; 2012 Jun; 46(6):802-11. PubMed ID: 22619477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo characterization and modulation of the glutathione/glutathione S-transferase system in cancer patients.
    Mulders TM; Keizer HJ; Breimer DD; Mulder GJ
    Drug Metab Rev; 1995; 27(1-2):191-229. PubMed ID: 7641576
    [No Abstract]   [Full Text] [Related]  

  • 13. Glutathione and cellular resistance to anti-cancer drugs.
    Hedley D; Chow S
    Methods Cell Biol; 1994; 42 Pt B():31-44. PubMed ID: 7533246
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies.
    Rosen LS; Brown J; Laxa B; Boulos L; Reiswig L; Henner WD; Lum RT; Schow SR; Maack CA; Keck JG; Mascavage JC; Dombroski JA; Gomez RF; Brown GL
    Clin Cancer Res; 2003 May; 9(5):1628-38. PubMed ID: 12738715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutathione
    Dong SC; Sha HH; Xu XY; Hu TM; Lou R; Li H; Wu JZ; Dan C; Feng J
    Drug Des Devel Ther; 2018; 12():3535-3547. PubMed ID: 30425455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies.
    Rosen LS; Laxa B; Boulos L; Wiggins L; Keck JG; Jameson AJ; Parra R; Patel K; Brown GL
    Clin Cancer Res; 2004 Jun; 10(11):3689-98. PubMed ID: 15173075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. gamma-Glutamyl transpeptidase, a glutathionase: its expression and function in carcinogenesis.
    Hanigan MH
    Chem Biol Interact; 1998 Apr; 111-112():333-42. PubMed ID: 9679564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical reversal of drug resistance.
    Goldstein LJ
    Curr Probl Cancer; 1995; 19(2):65-124. PubMed ID: 7600845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytotoxic Agents and Immune Checkpoint Inhibitors].
    Kawazoe A; Shitara K
    Gan To Kagaku Ryoho; 2017 Sep; 44(9):717-721. PubMed ID: 28912395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes.
    Mahadevan D; Sutton GR
    Expert Opin Investig Drugs; 2015 May; 24(5):725-33. PubMed ID: 25724698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.